The underlying immune mechanisms can be characterized through ex vivo assays in tumor-bearing mice treated with the anti-survivin agent, assessing survivin-specific antibody induction in serum by ELISA and T-cell reactivity using survivin tetramer staining. Here, BIRC5 is linked to neoplasm.